Arteris (NASDAQ:AIP – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Rosenblatt Securities in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $15.00 price target on the stock. Rosenblatt Securities’ price objective points to a potential upside of 109.50% from the company’s previous close.
Separately, Westpark Capital restated a “buy” rating and issued a $11.00 price objective on shares of Arteris in a report on Wednesday, July 31st.
Read Our Latest Report on Arteris
Arteris Stock Performance
Insiders Place Their Bets
In other news, VP Paul L. Alpern sold 3,615 shares of Arteris stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $7.13, for a total transaction of $25,774.95. Following the completion of the transaction, the vice president now directly owns 68,084 shares in the company, valued at approximately $485,438.92. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Wayne C. Cantwell sold 15,000 shares of Arteris stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $6.95, for a total transaction of $104,250.00. Following the completion of the transaction, the director now directly owns 243,198 shares in the company, valued at approximately $1,690,226.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Paul L. Alpern sold 3,615 shares of Arteris stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $7.13, for a total transaction of $25,774.95. Following the transaction, the vice president now owns 68,084 shares of the company’s stock, valued at $485,438.92. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 124,110 shares of company stock worth $902,044 over the last three months. Company insiders own 33.70% of the company’s stock.
Hedge Funds Weigh In On Arteris
A number of hedge funds have recently added to or reduced their stakes in the company. Essex Investment Management Co. LLC bought a new stake in Arteris in the 3rd quarter worth approximately $2,504,000. Silvercrest Asset Management Group LLC grew its position in Arteris by 25.2% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 711,903 shares of the company’s stock worth $5,211,000 after purchasing an additional 143,385 shares during the period. Acadian Asset Management LLC grew its position in Arteris by 28.1% in the 1st quarter. Acadian Asset Management LLC now owns 534,472 shares of the company’s stock worth $3,911,000 after purchasing an additional 117,312 shares during the period. Bank of New York Mellon Corp bought a new stake in Arteris in the 2nd quarter worth approximately $580,000. Finally, CloudAlpha Capital Management Limited Hong Kong bought a new stake in Arteris in the 2nd quarter worth approximately $554,000. 64.36% of the stock is currently owned by hedge funds and other institutional investors.
About Arteris
Arteris, Inc provides semiconductor interconnect intellectual property (IP) and System-on-Chip (Soc) Integration Automation software solutions (SIA) in the Americas, the Asia Pacific, Europe, and the Middle East. The company develops, licenses, and supports the on-chip interconnect fabric technology used in Soc designs and Network-on-Chip (NoC) interconnect IP.
See Also
- Five stocks we like better than Arteris
- Trading Halts Explained
- 2 Alternative Internet Stocks Staging a Breakout in 2024
- Stock Dividend Cuts Happen Are You Ready?
- Discover the 3 Best-Performing Biotech IPO Stocks of 2024
- What is the Nikkei 225 index?
- Hims & Hers: Why This Healthcare Stock’s Growth Makes It a Buy
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.